Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Non-Current Liabilities: 2014-2024

Historic Total Non-Current Liabilities for KalVista Pharmaceuticals (KALV) over the last 5 years, with Apr 2024 value amounting to $6.0 million.

  • KalVista Pharmaceuticals' Total Non-Current Liabilities was N/A to $30.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $30.6 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2024, which is N/A change from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Total Non-Current Liabilities of $6.0 million as of FY2024, which was up 469.06% from $1.1 million recorded in FY2020.
  • In the past 5 years, KalVista Pharmaceuticals' Total Non-Current Liabilities registered a high of $6.0 million during FY2024, and its lowest value of $1.1 million during FY2020.
  • Over the past 1 years, KalVista Pharmaceuticals' median Total Non-Current Liabilities value was $6.0 million (recorded in 2024), while the average stood at $6.0 million.
  • Data for KalVista Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY crashed of 68.37% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows KalVista Pharmaceuticals' Total Non-Current Liabilities stood at $1.1 million in 2020, then followed by $6.0 million in 2024.